Hyperresponsivity to the Serotonin Agonist m-Chlorophenylpiperazine in Alzheimer's Disease: A Controlled Study

Archives of General Psychiatry

Volumn 46, Issue 6, 1989, Pages 542-549

  Lawlor, Brian A ^a   Sunderland, Trey ^a   Mellow, Alan M ^a   Hill, James L ^a   Molchan, Susan E ^a   Murphy, Dennis L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; HYDROCORTISONE; PROLACTIN; SEROTONIN;

AGED; ALZHEIMER DISEASE; BEHAVIOR; BODY TEMPERATURE; CLINICAL ARTICLE; HUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RESTLESSNESS;

AGED; ALZHEIMER DISEASE; BLOOD PRESSURE; BRAIN; COMPARATIVE STUDY; FEMALE; HUMAN; HYDROCORTISONE; MALE; PERSONALITY INVENTORY; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; PULSE; SEROTONIN;

EID: 0024366757     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1989.01810060064010     Document Type: Article

References (58)

1. Murphy DL, Mueller EA, Hill JL, Tolliver T, Jacobsen FM: Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously and orally to healthy volunteers. Psychopharmacology, in press.
2. Charney DS, Woods SW, Goodman WK, Heninger GR: Serotonin function in anxiety: II. Effects of the serotonin agonist m-CPP in panic disorder patients and healthy subjects. Psychopharmacology 1987;92:14-24.
3. Mueller EA, Sunderland T, Murphy DL: Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist in humans. J Clin Endocrinol Metab 1985;61:1179-1184.
4. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL: Serotonergic responsivity in obsessive-compulsive disorder: Effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988;45:167-172.
5. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL: Serotonergic responsivity in obsessive-compulsive disorder: Comparison of patients and healthy controls. Arch Gen Psychiatry 1987;44:946-951.
6. Brewerton TD, Murphy DL, Mueller EA, Jimerson DC: Induction of migraine like headaches by the serotonin agonist m-chlorophenylpiperazine. Clin Pharmacol Ther 1988;43:605-609.
7. Kahn RS, Asnis GM, Wetzler S, Van Praag HM: Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 1988;96:360-364.
8. Davies P, Maloney AJ: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403-1405.
9. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delong MR: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982;215:1237-1239.
10. Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Bloom SR, Corsellis JAN: Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 1984;43:1574-1581.
11. Bondareff W, Mountjoy CQ, Roth M: Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurology 1982;32:164-168.
12. Davies P, Katzman R, Terry RD: Reduced somatostatin-like immunore-activity in cerebral cortex from cases of Alzheimer's disease and Alzheimer senile dementia. Nature 1980;288:279-280.
13. Yamamoto T, Hirano A: Nucleus raphe dorsalis in Alzheimer's disease: Neurofibrillary tangles and loss of large neurons. Ann Neurol 1985;17:573-577.
14. Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernas A, Nordberg A, Oreland L, Svennerholm L, Wiberg A, Winblad B: Biochemical changes in dementia disorders of the Alzheimer type (AD/SDAT). Neurobiol Aging 1983;4:261-271.
15. Bowen DM, Allen SJ, Benton JS, Goodhardt MJ, Hann EA, Palmer AM, Sims NR, Smith CCT, Spillane JA, Esiri MM, Neary D, Snowdon JS, Wilcock GK, Davison AN: Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 1983;1:266-272.
16. Palmer AM, Francis PT, Benton JS, Sims NR, Mann DMA, Neary D, Snowden JS, Bowen DM: Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem 1987;48:8-15.
17. Cross AJ, Crow TJ, Ferrier IN, Johnson JA: The selectivity of the reduction of S2-receptors in Alzheimer-type dementia. Neurobiol Aging 1986; 7:3-7.
18. Bergman I, Brane G, Gottfries CG, Jostell KG, Karlsson I, Svennerholm L: Alaproclate: A pharmacokinetic and biochemical study in patients with dementia of the Alzheimer type. Psychopharmacology 1983;80:279-283.
19. Gottfries CG: Dementia disorders and depression in the elderly: Biochemical aspects. Read before the 16th Collegium Internationale Neuro-Psychopharmacologicum Congress, Munich, Aug 17, 1988.
20. Traskman L, Asberg M, Bertilsson L, Sjostgrand L: Monoaminemetabolites in CSF and suicidal behavior. Arch Gen Psychiatry 1981;38:631-636.
21. Lawlor BA, Sunderland T, Mellow AM, Hill JL, Newhouse PA, Murphy DL: A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist, in elderly subjects. Biol Psychiatry, in press.
22. American Psychiatric Association, Committee on Nomenclature and Statistics: Diagnostic and Statistical Manual of Mental Disorders, ed 3, revised. Washington DC, American Psychiatric Association, 1987.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlam E: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group. Neurology 1984;34:939-944.
24. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
25. Van Kammen DP, Murphy DL: Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia 1975;44:215-224.
26. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC: Quantification of sleepiness: A new approach. Pathophysiology 1973;10:431-436.
27. Overall JE, Gorham DR: Brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
28. Cohen RM, Cohen MR, Weingartner H, Pickar D, Murphy DL: High-dose naloxone affects task performance in normal subjects. Psychiatry Res 1983;8:127-136.
29. Weingartner H, Kaye W, Smallberg SA, Ebert MH, Gillin JC, Sitaram N: Memory failures in progressive idiopathic dementia. J Abnorm Psychol 1981;90:187-196.
30. Buschke H: Selective reminding for analysis of memory and learning. J Verb Learn Verb Beh 1973;12:543-550.
31. Shih JC, Young H: The alteration of serotonin binding sites in aged human brain. Life Sci 1978;23:1441-1448.
32. Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Sims NR, Smith CCT, Spillane JA, Bowen DM, Davison AN: Biochemical evidence of selective nerve cell changes in the normal aging human and rat brain. J Neurochem 1983;41:256-265.
33. Middlemiss DN, Palmer AM, Edel N, Bowen DM: Binding of the novel serotonin agonist 8-hydroxy-2 (di-n-propylamino) tetralin in normal and Alzheimer brain. J Neurochem 1986;46:993-996.
34. Charig EM, Anderson IM, Robinson JM, Nutt DJ, Cowen PJ: L-tryptophan and prolactin release: Evidence for interaction between 5-HT1 and 5-HT2 receptors. Hum Psychopharmacol 1986;1:93-97.
35. Marchi M, Paudice P, Bella M, Raiteri M: Dicyclomine- and pirenzepine-sensitive muscarinic receptors mediate inhibition of serotonin release in different rat brain areas. Eur J Pharmacol 1986;129:353-357.
36. Vizi ES, Harsing LG, Zsula G: Evidence for the modulatory role of serotonin in acetylcholine release from striatal interneurons. Brain Res 1981;212:89-99.
37. Maj J, Lewandowska A: Central serotoninmimetic action of phenylpiperazines. Pol J Pharmacol Pharm 1980;32:495-504.
38. Rokosz-Pelc A, Antkiewicz-Michaluk L, Vetulani J: 5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: Comparison with quipazine. J Pharm Pharmacol 1980;32:220-222.
39. Mueller EA, Murphy DL, Sunderland T: Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: Evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology 1986; 89:388-391.
40. Invernizzi R, Cotecchia S, De Blasi A, Mennini T, Patuccini R, Samanin R: Effects of m-chlorophenylpiperazine on receptor binding and brain metabolism of monoamines in rats. Neurochem Int 1981;3:239-244.
41. Hamik A, Peroutka SJ: 1-(M-chlorophenyl) piperazine (mCPP) interactions with neurotransmitter receptors in human brain. Soc Neurosci Abs 1987;13:1237.
42. McKenney JD, Glennon RA: TFMPP may produce its stimulus effects via a 5-HT1B mechanism. Pharmacol Biochem Behav 1986;24:43-47.
43. Aulakh CS, Hill JL, Wozniak KM, Murphy DL: Fenfluramine-induced suppression of food intake and locomotor activity is differentially altered by the selective type A monoamine oxidase inhibitor clorgyline. Psychopharmacology 1988;95:313-317.
44. Aulakh CS, Zohar J, Wozniak KM, Hill JL, Murphy DL: Clorgyline treatment differentially affects m-chlorophenylpiperazine-induced neuroendocrine changes. Eur J Pharmacol 1988;150:239-246.
45. Glue PW, Cowen PJ, Nutt DJ, Kolakowska T, Grahme-Smith DG: The effect of lithium on 5-HT-mediated neuroendocrine responses and platelet 5-HT receptors. Psychopharmacology 1986;90:398-402.
46. Meltzer HY, Lowy M, Robertson A, Goodnick P, Perline R: Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders: III. Effect of antidepressants and lithium carbonate. Arch Gen Psychiatry 1984;41:391-397.
47. Charney DS, Heninger GR, Sternberg DE: Serotonin function and methanism of action of antidepressant treatment. Arch Gen Psychiatry 1984;41:359-365.
48. Wozniak KM, Aulakh CS, Hill JL, Murphy DL: Hyperthermia induced by m-CPP in the rat and its modification by antidepressant treatments. Psychopharmacology, in press.
49. Mueller EA, Murphy DL, Sunderland T, Jones J: A new postsynaptic serotonin agonist for studies in humans. Psychopharmacol Bull 1985;21:701-704.
50. Prinz PN, Christie C, Smallwood R, Vitaliano P, Bokan J, Vitiello MV, Martin D: Circadian temperature variation in healthy aged and in Alzheimer's disease. J Gerontol 1984;39:30-35.
51. Bagdy G, Szemeredi K, Zukowska-Grojec Z, Hill J, Murphy DL: M-Chlorophenylpiperazine increases blood pressure and heart rate in pithed and conscious rats. Life Sci 1987;41:775-782.
52. Altman HJ, Normile HJ: Enhancement of a previously learned aversive habit following pre-test administration of a variety of serotonergic antagonists in mice. Psychopharmacology 1986;90:24-27.
53. Archer T, Ogren SO, Johenssen C: The acute effects of p-chloroamphetamine on the retention of fear conditioning in the rat: Evidence for a role of serotonin in memory consolidation. Neurosci Lett 1981;25:75-81.
54. Essman WB: Neuromolecular modulation of experimentally induced retrograde amnesia. Confinia Neurologia 1973;35:1-22.
55. Ogren SO: Central serotonin neurones and learning in the rat, in Osborne NN (ed): Biology of Serotonergic Transmission. New York, John Wiley & Sons Inc, 1982, pp 317-334.
56. Ogren SO: Evidence for a role of brain serotonergic neurotransmission in avoidance learning. Acta Physiol Scand 1985;125(suppl 554):1-71.
57. Maura G, Raiteri M: Cholinergic terminals in rat hippocampus possess 5-HT1B receptors mediating inhibition of acetylcholine release. Eur J Pharmacol 1986;129:333-337.
58. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA III, Murphy DL: Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: A dose-response study. Arch Gen Psychiatry 1987;44:418-426.